Josephine A. Mauskopf

Expertise

Health Economics
Health Care Interventions
Pharmacoeconomics
Patient-Reported Outcomes

Biography

Josephine Mauskopf, PhD, MHA, is vice president of health economics at RTI Health Solutions. She has extensive experience both as a consultant and within the pharmaceutical industry designing and implementing pharmacoeconomic research strategies. She has designed pharmacoeconomic research programs for drugs for bacterial infections, viral infections, psychiatric illness, and neurologic diseases. Dr. Mauskopf has estimated budget impacts for new products for schizophrenia, bipolar disease, breast cancer, and HIV infection. She has estimated the cost-effectiveness of antiretroviral drugs, as well as drugs for treating herpes zoster, epilepsy, neonatal respiratory distress syndrome, digoxin toxicity, community-acquired pneumonia, intra-abdominal infections, and primary pulmonary hypertension. Dr. Mauskopf was previously vice president at MEDTAP International, department head of economics research at Burroughs Wellcome, and director of pharmacoeconomics research for anti-virals and anti-infectives at Glaxo Wellcome. Dr. Mauskopf is editor-in-chief of Value in Health. She has presented her research at numerous national and international symposia, and has published extensively in journals.

Education

PhD, Economics, Duke University; MHA, Health Administration, Duke University; MA, Physiology and Pharmacology, Duke University.

Selected Publications

Richter, A., Hauber, B., Simpson, K., Mauskopf, J.A., & Yin, D. (2002). A Monte Carlo simulation for modelling outcomes of AIDS treatment regimens. Pharmacoeconomics, 20 (4):215-224.

Mauskopf, J.A., Richter, A., Annemans, L., & Maclaine, G. (2000 Sep). Cost-effectiveness model of cytomegalovirus management strategies in renal transplantation. Comparing valaciclovir prophylaxis with current practice. Pharmacoeconomics, 18 (3):239-251.

Mauskopf, J. (2000 Jul). Meeting the NICE Requirements: A Markov Model Approach. Value in Health, 3 (4):287-293.

Mauskopf, J.A., Cates, S.C., Griffin, A.D., Neighbors, D.M., Lamb, S.C., & Rutherford, C. (2000 Jun). Cost effectiveness of zanamivir for the treatment of influenza in a high risk population in Australia. Pharmacoeconomics, 17 (6):611-620.

Mauskopf, J.A., Tolson, J.M., Simpson, K.N., Pham, S.V., & Albright, J. (2000 Apr 1). Impact of zidovudine-based triple combination therapy on an AIDS drug assistance program. Journal of Acquired Immune Deficiency Syndromes, 23 (4):302-313.

Mauskopf, J.A., Cates, S.C., & Griffin, A.D. (1999). A pharmacoeconomic model for the treatment of influenza. Pharmacoeconomics, 16 (Suppl 1):73-84.

Lacey, L., Mauskopf, J., Lindrooth, R., Pham, S., Saag, M., & Sawyer, W. (1999). A prospective cost-consequence analysis of adding lamivudine to zidovudine-containing antiretroviral treatment regimens for HIV infection in the US. Pharmacoeconomics, 15 (Suppl 1):23-37.

Bala, M.V., Mauskopf, J.A., & Wood, L.L. (1999 Jan). Willingness to pay as a measure of health benefits. Pharmacoeconomics, 15 (1):9-18.

Grant, D.M., Mauskopf, J.A., Bell, L., & Austin, R. (1997 Mar). Comparison of valaciclovir and acyclovir for the treatment of herpes zoster in immunocompetent patients over 50 years of age: a cost-consequence model. Pharmacotherapy, 17 (2):333-341.

Mauskopf, J.A., Paul, J.E., Wichman, D.S., White, A.D., & Tilson, H.H. (1996 Jul 10). Economic impact of treatment of HIV-positive pregnant women and their newborns with zidovudine. Implications for HIV screening. JAMA, 276 (2):132-138.

View all publications by Josephine A. Mauskopf…